{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:15:45Z","timestamp":1784200545059,"version":"3.55.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02337-7","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:59:58Z","timestamp":1778731198000},"page":"1171-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Cardiorenal Protective Therapies in Lupus Nephritis"],"prefix":"10.1007","volume":"86","author":[{"given":"Irene Martin","family":"Capon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justo","family":"Sandino-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-6973","authenticated-orcid":false,"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"1","key":"2337_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14427","volume":"30","author":"STY Teoh","year":"2025","unstructured":"Teoh STY, Yap DYH, Yung S, Chan TM. Lupus nephritis and chronic kidney disease: a scoping review. Nephrology. 2025;30(1):e14427. https:\/\/doi.org\/10.1111\/nep.14427.","journal-title":"Nephrology"},{"issue":"3","key":"2337_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/rheumatology\/keae236","volume":"64","author":"F Farinha","year":"2025","unstructured":"Farinha F, Barreira S, Couto M, Cunha M, Fonseca D, Freitas R, et al. Risk of chronic kidney disease in 260 patients with lupus nephritis: analysis of a nationwide multicentre cohort with up to 35 years of follow-up. Rheumatology. 2025;64(3):1201\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keae236.","journal-title":"Rheumatology"},{"issue":"9","key":"2337_CR3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/ndt\/gfae034","volume":"39","author":"S Abd ElHafeez","year":"2024","unstructured":"Abd ElHafeez S, Kramer A, Arici M, Arnol M, \u00c5sberg A, Bell S, et al. Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry. Nephrol Dial Transpl. 2024;39(9):1449\u201360. https:\/\/doi.org\/10.1093\/ndt\/gfae034.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"2337_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ekir.2024.10.021","volume":"10","author":"C Chrysostomou","year":"2025","unstructured":"Chrysostomou C, Faustini F, Gunnarsson I, Segelmark M, Carrero JJ, Barany P, et al. Long-term outcomes of lupus nephritis in comparison to other CKD etiologies. Kidney Int Rep. 2025;10(1):157\u201368. https:\/\/doi.org\/10.1016\/j.ekir.2024.10.021.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"2337_CR5","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1093\/rheumatology\/kead624","volume":"63","author":"T Zoshima","year":"2024","unstructured":"Zoshima T, Hara S, Suzuki K, Yoshida M, Konishi M, Hibino S, et al. Long-term outcomes of lupus nephritis with low-level proteinuria: a multicentre, retrospective study. Rheumatology. 2024;63(11):3074\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kead624.","journal-title":"Rheumatology"},{"key":"2337_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00185","volume":"8","author":"J Carracedo","year":"2020","unstructured":"Carracedo J, Alique M, Vida C, Bodega G, Cepri\u00e1n N, Morales E, et al. Mechanisms of cardiovascular disorders in patients with chronic kidney disease: a process related to accelerated senescence. Front Cell Dev Biol. 2020;8:185. https:\/\/doi.org\/10.3389\/fcell.2020.00185.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2337_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000546177","volume":"5","author":"M Vakhshoori","year":"2025","unstructured":"Vakhshoori M, Heidari-Bateni G, Mathew RO, Abdipour A, Daher NS, Hiremath S, et al. Cardiovascular events in lupus nephritis: a systematic review and meta-analysis. Glomerular Dis. 2025;5(1):261\u201377. https:\/\/doi.org\/10.1159\/000546177.","journal-title":"Glomerular Dis"},{"issue":"6","key":"2337_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/ndt\/gfaf033","volume":"40","author":"YKO Teng","year":"2025","unstructured":"Teng YKO, Frangou E, Kronbichler A, Bruchfeld A, Caravaca-Fontan F, Floege J, et al. Disease-modifying anti-nephropathic drugs (DMANDs)\u2014a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA). Nephrol Dial Transpl. 2025;40(6):1243\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfaf033.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"2337_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nefro.2024.07.005","volume":"45","author":"E Morales","year":"2025","unstructured":"Morales E, Galindo M. Nefritis l\u00fapica: 10 cuestiones para pensar. Nefrologia. 2025;45(2):101\u20135. https:\/\/doi.org\/10.1016\/j.nefro.2024.07.005.","journal-title":"Nefrologia"},{"key":"2337_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.09.007","author":"A Fanouriakis","year":"2025","unstructured":"Fanouriakis A, Kostopoulou M, Anders HJ, Andersen J, Aringer M, Beresford MW, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.09.007.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2337_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2337_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic Lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762.","journal-title":"Ann Rheum Dis"},{"key":"2337_CR13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000858","author":"M Abinti","year":"2025","unstructured":"Abinti M, Patricio-Liebana M, Anders HJ. Lupus nephritis: unmet needs and evolving solutions. Clin J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.2215\/CJN.0000000858.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2337_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","volume":"20","author":"J Lichtnekert","year":"2024","unstructured":"Lichtnekert J, Anders HJ. Lupus nephritis-related chronic kidney disease. Nat Rev Rheumatol. 2024;20(11):699\u2013711. https:\/\/doi.org\/10.1038\/s41584-024-01158-w.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"2337_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae237","volume":"17","author":"F Caravaca-Font\u00e1n","year":"2024","unstructured":"Caravaca-Font\u00e1n F, Del Vecchio L, Praga M, Floege J, Zoccali C. Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a CKJ controversy. Clin Kidney J. 2024;17(9):sfae237. https:\/\/doi.org\/10.1093\/ckj\/sfae237.","journal-title":"Clin Kidney J"},{"issue":"5","key":"2337_CR16","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1681\/ASN.2006050445","volume":"18","author":"WBA Eijkelkamp","year":"2007","unstructured":"Eijkelkamp WBA, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540\u20136. https:\/\/doi.org\/10.1681\/ASN.2006050445.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2337_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/147323000903700335","volume":"37","author":"N Kitamura","year":"2009","unstructured":"Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin converting enzyme inhibitors and an angiotensin II receptor blocker in patients with Lupus nephritis. J Int Med Res. 2009;37(3):892\u20138. https:\/\/doi.org\/10.1177\/147323000903700335.","journal-title":"J Int Med Res"},{"key":"2337_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04815-5","author":"OE Tayer-Shifman","year":"2025","unstructured":"Tayer-Shifman OE, Kenis I, Benchetrit S, Bar-Ziv D, Pri-Paz Basson Y, Levy Y, et al. Clinical experience with sodium\u2013glucose transport 2 (SGLT2) inhibitors in patients with systemic Lupus erythematosus. Int Urol Nephrol. 2025. https:\/\/doi.org\/10.1007\/s11255-025-04815-5.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2337_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2215\/CJN.11881019","volume":"15","author":"JFE Mann","year":"2020","unstructured":"Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, et al. Safety of liraglutide in type 2 diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2020;15(4):465\u201373. https:\/\/doi.org\/10.2215\/CJN.11881019.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2337_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"11","key":"2337_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31(11):1409\u201317. https:\/\/doi.org\/10.1007\/s00296-011-1999-3.","journal-title":"Rheumatol Int"},{"issue":"14","key":"2337_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","volume":"77","author":"A Yafasova","year":"2021","unstructured":"Yafasova A, Fosb\u00f8l EL, Schou M, Baslund B, Faurschou M, Docherty KF, et al. Long-term cardiovascular outcomes in systemic Lupus erythematosus. J Am Coll Cardiol. 2021;77(14):1717\u201327. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.029.","journal-title":"J Am Coll Cardiol"},{"key":"2337_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf464","author":"F Kharouf","year":"2025","unstructured":"Kharouf F, Mehta P, Li Q, Gladman DD, Whittall Garcia LP, Touma Z. Venous thromboembolism in patients with Lupus Nephritis: frequency and risk factors\u2014a cohort study. Rheumatology. 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf464.","journal-title":"Rheumatology"},{"issue":"9","key":"2337_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3899\/jrheum.2024-1087","volume":"52","author":"K Cohen-Hagai","year":"2025","unstructured":"Cohen-Hagai K, Saban M, Benchetrit S, Bar-Ziv D, Nacasch N, Shashar M, et al. Prevalence, risk factors, and outcomes of chronic kidney disease in patients with systemic lupus erythematosus with and without lupus nephritis. J Rheumatol. 2025;52(9):902\u20138. https:\/\/doi.org\/10.3899\/jrheum.2024-1087.","journal-title":"J Rheumatol"},{"issue":"12","key":"2337_CR25","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1016\/j.ekir.2024.09.028","volume":"9","author":"DYH Yap","year":"2024","unstructured":"Yap DYH, Xu X, Juliao PC, Tang CSO, Ng L, Milea D, et al. Long-term kidney outcome of lupus nephritis by renal response status. Kidney Int Rep. 2024;9(12):3532\u201341. https:\/\/doi.org\/10.1016\/j.ekir.2024.09.028.","journal-title":"Kidney Int Rep."},{"issue":"2","key":"2337_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.05040513","volume":"9","author":"SV Parikh","year":"2014","unstructured":"Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal Flare as a Predictor of Incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol. 2014;9(2):279\u201384. https:\/\/doi.org\/10.2215\/CJN.05040513.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2337_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.7326\/M18-1570","volume":"170","author":"A Jorge","year":"2019","unstructured":"Jorge A, Wallace ZS, Lu N, Zhang Y, Choi HK. Renal transplantation and survival among patients with lupus nephritis: a cohort study. Ann Intern Med. 2019;170(4):240\u20137. https:\/\/doi.org\/10.7326\/M18-1570.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2337_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nefroe.2023.05.006","volume":"43","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera JE, Garc\u00eda-Carro C, \u00c1vila AI, Espino M, Espinosa M, Fern\u00e1ndez-Ju\u00e1rez G, et al. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis. Nefrolog\u00eda (English Edition). 2023;43(1):6\u201347. https:\/\/doi.org\/10.1016\/j.nefroe.2023.05.006.","journal-title":"Nefrolog\u00eda (English Edition)."},{"issue":"1","key":"2337_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mej\u00eda-Vilet JM, Floege J. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1):S1-69. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002.","journal-title":"Kidney Int"},{"issue":"34","key":"2337_CR30","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"3S","key":"2337_CR31","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-87. https:\/\/doi.org\/10.1016\/j.kint.2020.11.003.","journal-title":"Kidney Int"},{"issue":"4S","key":"2337_CR32","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"6","key":"2337_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0961203320913616","volume":"29","author":"JH Kang","year":"2020","unstructured":"Kang JH, Xu H, Choi SE, Park DJ, Lee JK, Kwok SK, et al. Obesity increases the incidence of new-onset lupus nephritis and organ damage during follow-up in patients with systemic lupus erythematosus. Lupus. 2020;29(6):578\u201386. https:\/\/doi.org\/10.1177\/0961203320913616.","journal-title":"Lupus"},{"issue":"12","key":"2337_CR34","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1177\/09612033251375856","volume":"34","author":"F Cuervo","year":"2025","unstructured":"Cuervo F, Enfrein A, Anders HJ, Houssiau FA, Tamirou F. Obesity is an independent poor prognostic factor in lupus nephritis. Lupus. 2025;34(12):1292\u20137. https:\/\/doi.org\/10.1177\/09612033251375856.","journal-title":"Lupus"},{"issue":"5S","key":"2337_CR35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"Suppl 12","key":"2337_CR36","first-page":"S283","volume":"10","author":"HS Mackenzie","year":"1999","unstructured":"Mackenzie HS, Ziai F, Omer SA, Nadim MK, Taal MW. Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. J Am Soc Nephrol. 1999;10(Suppl 12):S283-286.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2337_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036171","volume":"7","author":"BT Bateman","year":"2012","unstructured":"Bateman BT, Shaw KM, Kuklina EV, Callaghan WM, Seely EW, Hern\u00e1ndez-D\u00edaz S. Hypertension in women of reproductive age in the United States: NHANES 1999-2008. PLoS ONE. 2012;7(4):e36171. https:\/\/doi.org\/10.1371\/journal.pone.0036171.","journal-title":"PLoS ONE"},{"key":"2337_CR38","doi-asserted-by":"publisher","unstructured":"Dall\u2019Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305\u201313. https:\/\/doi.org\/10.1002\/art.39026.","DOI":"10.1002\/art.39026"},{"issue":"1","key":"2337_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000123","volume":"2","author":"F Tamirou","year":"2015","unstructured":"Tamirou F, Lauwerys BR, Dall\u2019Era M, Mackay M, Rovin B, Cervera R, et al. A proteinuria cut-off level of 0.7 g\/day after 12\u2005months of treatment best predicts long-term renal outcome in Lupus Nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. https:\/\/doi.org\/10.1136\/lupus-2015-000123.","journal-title":"Lupus Sci Med"},{"issue":"6","key":"2337_CR40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic Lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768\u201379. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221733.","journal-title":"Ann Rheum Dis"},{"key":"2337_CR41","doi-asserted-by":"crossref","unstructured":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857\u201363.","DOI":"10.1016\/S0140-6736(96)11445-8"},{"issue":"2","key":"2337_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1570161115666170502104809","volume":"16","author":"N Louvis","year":"2018","unstructured":"Louvis N, Coulson J. Renoprotection by direct renin inhibition: a systematic review and meta-analysis. Curr Vasc Pharmacol. 2018;16(2):157\u201367. https:\/\/doi.org\/10.2174\/1570161115666170502104809.","journal-title":"Curr Vasc Pharmacol"},{"issue":"7","key":"2337_CR43","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","volume":"18","author":"K Tse","year":"2003","unstructured":"Tse K, Lam M, Yip P, Li F, Choy B, Lai K, et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transpl. 2003;18(7):1316\u201320.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"2337_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clim.2010.03.008","volume":"136","author":"H Shimazu","year":"2010","unstructured":"Shimazu H, Kinoshita K, Hino S, Yano T, Kishimoto K, Nagare Y, et al. Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol. 2010;136(2):188\u201396. https:\/\/doi.org\/10.1016\/j.clim.2010.03.008.","journal-title":"Clin Immunol"},{"issue":"1","key":"2337_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ndt\/gfad154","volume":"39","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera JE, Bakkaloglu SA, Bolignano D, Nistor I, Sarafidis PA, Stoumpos S, et al. Chronic kidney disease: the missing concept in the 2019 EULAR\/ERA-EDTA recommendations for Lupus nephritis. Nephrol Dial Transplant. 2023;39(1):151\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfad154.","journal-title":"Nephrol Dial Transplant"},{"key":"2337_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1105676","volume":"3","author":"E Morales","year":"2023","unstructured":"Morales E, Sandino J, Galindo M. Lupus nephropathy beyond immunosuppression: searching for nephro and cardioprotection. Front Nephrol. 2023;3:1105676. https:\/\/doi.org\/10.3389\/fneph.2023.1105676.","journal-title":"Front Nephrol"},{"issue":"6","key":"2337_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000517020","volume":"52","author":"H Trujillo","year":"2021","unstructured":"Trujillo H, Caravaca-Font\u00e1n F, Caro J, Morales E, Praga M. The forgotten antiproteinuric properties of diuretics. Am J Nephrol. 2021;52(6):435\u201349. https:\/\/doi.org\/10.1159\/000517020.","journal-title":"Am J Nephrol"},{"issue":"10","key":"2337_CR48","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ki.2011.48","volume":"79","author":"JP Bertocchio","year":"2011","unstructured":"Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):1051\u201360. https:\/\/doi.org\/10.1038\/ki.2011.48.","journal-title":"Kidney Int"},{"issue":"2","key":"2337_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","volume":"145","author":"K Douglas","year":"2006","unstructured":"Douglas K, O\u2019Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117\u201324. https:\/\/doi.org\/10.7326\/0003-4819-145-2-200607180-00009.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2337_CR50","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006\u201316. https:\/\/doi.org\/10.1681\/ASN.2006010012.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2337_CR51","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1507\/endocrj.k11e-080","volume":"58","author":"M Abe","year":"2011","unstructured":"Abe M, Maruyama N, Yoshida Y, Ito M, Okada K, Soma M. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr J. 2011;58(8):663\u201374. https:\/\/doi.org\/10.1507\/endocrj.k11e-080.","journal-title":"Endocr J"},{"issue":"Suppl 1","key":"2337_CR52","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1681\/asn.2004110958","volume":"16","author":"VM Campese","year":"2005","unstructured":"Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005;16(Suppl 1):S11-17. https:\/\/doi.org\/10.1681\/asn.2004110958.","journal-title":"J Am Soc Nephrol"},{"issue":"7645","key":"2337_CR53","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","volume":"336","author":"GFM Strippoli","year":"2008","unstructured":"Strippoli GFM, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645\u201351. https:\/\/doi.org\/10.1136\/bmj.39472.580984.AE.","journal-title":"BMJ"},{"issue":"5","key":"2337_CR54","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.semarthrit.2015.10.010","volume":"45","author":"K Tselios","year":"2016","unstructured":"Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45(5):604\u201310. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2337_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10067-014-2527-0","volume":"33","author":"E Pokroy-Shapira","year":"2014","unstructured":"Pokroy-Shapira E, Gelernter I, Molad Y. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clin Rheumatol. 2014;33(5):649\u201357. https:\/\/doi.org\/10.1007\/s10067-014-2527-0.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2337_CR56","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0961203317739129","volume":"27","author":"CC Mok","year":"2018","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus. 2018;27(5):722\u20137. https:\/\/doi.org\/10.1177\/0961203317739129.","journal-title":"Lupus"},{"issue":"1","key":"2337_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9171715","volume":"2021","author":"J Zhang","year":"2021","unstructured":"Zhang J, Lu X, Feng J, Li H, Wang S. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a systematic review and meta\u2010analysis. BioMed Res Int. 2021;2021(1):9171715. https:\/\/doi.org\/10.1155\/2021\/9171715.","journal-title":"BioMed Res Int"},{"issue":"1","key":"2337_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04370-2","volume":"26","author":"GG Mathew","year":"2025","unstructured":"Mathew GG, Sundaramurthy S, Muthuperumal P, Jayaprakash V. Role of hydroxychloroquine in primary glomerular disease\u2014a systematic review and meta-analysis of the current evidence. BMC Nephrol. 2025;26(1):431. https:\/\/doi.org\/10.1186\/s12882-025-04370-2.","journal-title":"BMC Nephrol"},{"issue":"4","key":"2337_CR59","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00431-023-04837-0","volume":"182","author":"FS Gheet","year":"2023","unstructured":"Gheet FS, Dawoud HES, El-Shahaby WA, Elrifaey SM, Abdelnabi HH. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur J Pediatr. 2023;182(4):1685\u201395. https:\/\/doi.org\/10.1007\/s00431-023-04837-0.","journal-title":"Eur J Pediatr"},{"issue":"11","key":"2337_CR60","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"MEB Clowse","year":"2006","unstructured":"Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640\u20137. https:\/\/doi.org\/10.1002\/art.22159.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2337_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/nep.13991","volume":"27","author":"C Tang","year":"2022","unstructured":"Tang C, Si FL, Yao YX, Lv JC, Shi SF, Chen YQ, et al. The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: a retrospective cohort study. Nephrology. 2022;27(2):155\u201361. https:\/\/doi.org\/10.1111\/nep.13991.","journal-title":"Nephrology"},{"issue":"15","key":"2337_CR62","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"2337_CR63","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1172\/JCI112013","volume":"76","author":"S Anderson","year":"1985","unstructured":"Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76(2):612\u20139. https:\/\/doi.org\/10.1172\/JCI112013.","journal-title":"J Clin Invest"},{"issue":"9","key":"2337_CR64","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/annrheumdis-2022-222512","volume":"81","author":"E Morales","year":"2022","unstructured":"Morales E, Galindo M. SGLT2 inhibitors in Lupus Nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. 2022;81(9):1337\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222512.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2337_CR65","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/art.43037","volume":"77","author":"KSK Ma","year":"2025","unstructured":"Ma KSK, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors for the primary prevention of cardiovascular, renal events, and safety outcomes in patients with Systemic Lupus Erythematosus and comorbid Type 2 Diabetes: a population-based target trial emulation. Arthritis Rheumatol. 2025;77(4):414\u201322. https:\/\/doi.org\/10.1002\/art.43037.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2337_CR66","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/ard-2023-224242","volume":"82","author":"XY Zhao","year":"2023","unstructured":"Zhao XY, Li SS, He YX, Yan LJ, Lv F, Liang QM, et al. SGLT2 inhibitors alleviated podocyte damage in Lupus Nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023;82(10):1328\u201340. https:\/\/doi.org\/10.1136\/ard-2023-224242.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2337_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578","volume":"7","author":"FS Yen","year":"2024","unstructured":"Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JCC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with Systemic Lupus Erythematosus. JAMA Netw Open. 2024;7(6):e2416578. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.16578.","journal-title":"JAMA Netw Open"},{"key":"2337_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf548","author":"I Ram\u00edrez-Mulhern","year":"2025","unstructured":"Ram\u00edrez-Mulhern I, Navarro-S\u00e1nchez V, Rivero-Otamendi E, S\u00e1nchez-Mej\u00eda DE, Zavala-Miranda MF, Mejia-Vilet JM. Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf548.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"2337_CR69","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","volume":"34","author":"JF Gautier","year":"2008","unstructured":"Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in Type 2 Diabetes. Diabetes Metab. 2008;34(Suppl 2):S65-72. https:\/\/doi.org\/10.1016\/S1262-3636(08)73397-4.","journal-title":"Diabetes Metab"},{"issue":"10193","key":"2337_CR70","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in Type 2 Diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)31150-X.","journal-title":"Lancet"},{"issue":"8","key":"2337_CR71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2337_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"1","key":"2337_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"issue":"5","key":"2337_CR74","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1093\/rheumatology\/keae547","volume":"64","author":"PM Carlucci","year":"2025","unstructured":"Carlucci PM, Cohen B, Saxena A, Belmont HM, Masson M, Gold HT, et al. A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients. Rheumatology (Oxford). 2025;64(5):3085\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keae547.","journal-title":"Rheumatology (Oxford)"},{"key":"2337_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/art.43403","author":"A Jorge","year":"2025","unstructured":"Jorge A, Patel AV, Zhou B, Zhang L, Choi H. Glucagon-like peptide-1 receptor agonist use and the risk of adverse cardiac and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43403.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2337_CR76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","volume":"45","author":"V Marzolla","year":"2022","unstructured":"Marzolla V, Feraco A, Limana F, Kolkhof P, Armani A, Caprio M. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest. 2022;45(1):215\u201320. https:\/\/doi.org\/10.1007\/s40618-021-01635-z.","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2337_CR77","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s40262-023-01312-9","volume":"62","author":"R Heinig","year":"2023","unstructured":"Heinig R, Eissing T. The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone. Clin Pharmacokinet. 2023;62(12):1673\u201393. https:\/\/doi.org\/10.1007\/s40262-023-01312-9.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2337_CR78","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"issue":"23","key":"2337_CR79","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"2337_CR80","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"10","key":"2337_CR81","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1016\/j.ekir.2025.07.039","volume":"10","author":"M Sun","year":"2025","unstructured":"Sun M, Xiao F, Chen X, Wang L, Dai H. Finerenone as a nonsteroidal mineralocorticoid receptor antagonist for Lupus nephritis. Kidney Int Rep. 2025;10(10):3694\u20135. https:\/\/doi.org\/10.1016\/j.ekir.2025.07.039.","journal-title":"Kidney Int Rep"},{"issue":"Supplement_1","key":"2337_CR82","doi-asserted-by":"publisher","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","volume":"40","author":"BL Neuen","year":"2025","unstructured":"Neuen BL, Yeung EK, Rangaswami J, Vaduganathan M. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrol Dial Transplant. 2025;40(Supplement_1):i59-69. https:\/\/doi.org\/10.1093\/ndt\/gfae258.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2337_CR83","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.2013080830","volume":"25","author":"D de Zeeuw","year":"2014","unstructured":"de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083\u201393. https:\/\/doi.org\/10.1681\/ASN.2013080830.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2337_CR84","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/11319550-000000000-00000","volume":"24","author":"JJ Swigris","year":"2010","unstructured":"Swigris JJ, Brown KK. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs. 2010;24(1):49\u201354. https:\/\/doi.org\/10.2165\/11319550-000000000-00000.","journal-title":"BioDrugs"},{"key":"2337_CR85","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","DOI":"10.1056\/NEJMoa2204233"},{"key":"2337_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfag016","author":"E Morales","year":"2026","unstructured":"Morales E, Galindo M. Clinical trials for lupus nephritis. It is time for change. Clin Kidney J. 2026. https:\/\/doi.org\/10.1093\/ckj\/sfag016.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2337_CR87","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","volume":"39","author":"F Caravaca-Font\u00e1n","year":"2024","unstructured":"Caravaca-Font\u00e1n F, Stevens K, Padr\u00f3n M, Huerta A, Montomoli M, Villa J, et al. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrol Dial Transplant. 2024;39(2):328\u201340. https:\/\/doi.org\/10.1093\/ndt\/gfad175.","journal-title":"Nephrol Dial Transplant"},{"issue":"22","key":"2337_CR88","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"23","key":"2337_CR89","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"issue":"4","key":"2337_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"2337_CR91","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"13","key":"2337_CR92","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"issue":"1","key":"2337_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.96","volume":"3","author":"JA Udell","year":"2020","unstructured":"Udell JA, Yuan Z, Ryan P, Rush T, Sicignano NM, Galitz M, et al. Cardiovascular outcomes and mortality after initiation of canagliflozin: analyses from the EASEL Study. Endocrinol Diabetes Metab. 2020;3(1):e00096. https:\/\/doi.org\/10.1002\/edm2.96.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"4","key":"2337_CR94","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"24","key":"2337_CR95","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"9","key":"2337_CR96","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"21","key":"2337_CR97","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"7","key":"2337_CR98","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.2249","volume":"23","author":"SD Solomon","year":"2021","unstructured":"Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217\u201325. https:\/\/doi.org\/10.1002\/ejhf.2249.","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2337_CR99","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"1","key":"2337_CR100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","volume":"151","author":"KF Docherty","year":"2025","unstructured":"Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, et al. Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF Trial. Circulation. 2025;151(1):45\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072011.","journal-title":"Circulation"},{"issue":"10184","key":"2337_CR101","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(19)30772-X.","journal-title":"Lancet"},{"issue":"6","key":"2337_CR102","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schrader","year":"2005","unstructured":"Schrader J, L\u00fcders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218\u201326. https:\/\/doi.org\/10.1161\/01.STR.0000166048.35740.a9.","journal-title":"Stroke"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02337-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02337-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02337-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:49:37Z","timestamp":1784198977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02337-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02337-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data presented in this review are published and available in the referenced sources. No additional source data are required.","order":2,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed equally to the drafting and writing of this review. In addition, all authors have read and approve the final version of the manuscript, and agree to be accountable for the work.","order":3,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}